GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Pretax Margin %

Century Therapeutics (Century Therapeutics) Pretax Margin % : -3,281.99% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Century Therapeutics's Pre-Tax Income for the three months ended in Mar. 2024 was $-28.06 Mil. Century Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.86 Mil. Therefore, Century Therapeutics's pretax margin for the quarter that ended in Mar. 2024 was -3,281.99%.

The historical rank and industry rank for Century Therapeutics's Pretax Margin % or its related term are showing as below:

IPSC' s Pretax Margin % Range Over the Past 10 Years
Min: -9693.21   Med: -4273.81   Max: -2516.66
Current: -9693.21


IPSC's Pretax Margin % is ranked worse than
90.42% of 1033 companies
in the Biotechnology industry
Industry Median: -172.84 vs IPSC: -9693.21

Century Therapeutics Pretax Margin % Historical Data

The historical data trend for Century Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Pretax Margin % Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
- - - -2,516.66 -6,030.96

Century Therapeutics Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,747.44 -32,667.68 -21,708.11 -15,025.00 -3,281.99

Competitive Comparison of Century Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Century Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Pretax Margin % falls into.



Century Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Century Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-134.792/2.235
=-6,030.96 %

Century Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-28.061/0.855
=-3,281.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Century Therapeutics  (NAS:IPSC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Century Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Century Therapeutics (Century Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Executives
Luis Borges officer: Chief Scientific Officer TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Daphne Quimi director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez director ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky officer: President of R&D C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Adrienne Farid officer: Chief Operations Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti officer: Chief Technology Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Osvaldo Flores officer: Chief Executive Officer C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr officer: VP of Finance and Operations C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104